by GlobeNewsWire | Jun 3, 2016 | Globe Newswire
– 60% overall response rate; 96% achieved stable disease or better – – 12.9 mo. median and 60% 1-year overall survival in combination with Avastin® – – Safety profile remains favorable; no dose-limiting toxicities to date – CHICAGO, June 03, 2016 (GLOBE NEWSWIRE)...
by GlobeNewsWire | May 24, 2016 | Globe Newswire
BRANFORD, Conn., May 24, 2016 (GLOBE NEWSWIRE) — BioXcel Corporation, a global leader in real-time big data platforms for the discovery and development of transformative patient treatments, today announced the initiation of a strategic collaboration with Alnylam...
by GlobeNewsWire | May 11, 2016 | Globe Newswire
NEWARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate...
by GlobeNewsWire | May 3, 2016 | Globe Newswire
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations Actively Enrolling Patients Across Multiple Sites in Clinical Study to Investigate Novel Enzyme Replacement Therapy for Pompe Disease Company to Remain Within...
by GlobeNewsWire | May 2, 2016 | Globe Newswire
SEATTLE, May 02, 2016 (GLOBE NEWSWIRE) — Researchers from the University of Pennsylvania today announced new animal study data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis...
